The AVEO Oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise, and a proven track record for success in bringing important new therapies to patients.
Michael P. Bailey
PRESIDENT AND CEO
Michael P. Bailey serves as president and chief executive officer of AVEO and a member of the company’s board of directors, bringing more than 20 years of experience in the pharmaceutical industry to the company. He joined AVEO in 2010 as the company’s chief commercial officer, was named chief business officer in 2013 and assumed his current roles in January 2015. Mr. Bailey joined AVEO from Synta Pharmaceuticals, where he served as senior vice president, business development, and chief commercial officer since 2008. Prior to joining Synta, Mr. Bailey led ImClone Systems' (now Eli Lilly) Worldwide Commercial Organization. During his nine year tenure at ImClone, he was responsible for commercial aspects of the planning and launch of ERBITUX® (cetuximab) across multiple oncology indications, as well as new product planning for the ImClone development portfolio, which included CYRAMZA® (ramucirumab) and necitumumab. In addition, Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and worldwide partnerships. Prior to joining ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., and was a key member of their global commercial partnership teams. Mr. Bailey started his career in the pharmaceutical industry as part of SmithKline Beecham's Executive Marketing Development Program, where he held a variety of commercial roles, including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the Mendoza College of Business at University of Notre Dame.
Michael N. Needle, M.D.
CHIEF MEDICAL OFFICER
Michael N. Needle, M.D., serves as chief medical officer of AVEO, and brings more than 15 years of pharmaceutical industry experience in drug development and regulatory affairs. This includes central roles in the development of oncology and hematology drugs, including Erbitux® (cetuximab), Revlimid® (lenalidomide) and Pomalyst® (pomolidimide). He most recently served as the Chief Medical Officer of Array BioPharma. Prior to Array, Dr. Needle was Chief Medical Officer of the Multiple Myeloma Research Foundation and Consortium (MMRF). Prior to MMRF, he held multiple Vice President level positions at Celgene in Clinical Research and Development in Oncology, Strategic Medical Business Development, and Pediatric Strategy. Dr. Needle also served as the Vice President of Clinical Affairs at ImClone Systems Incorporated. Dr. Needle did his fellowship in Pediatric Hematology / Oncology at the Children's Hospital Medical Center and the Fred Hutchinson Cancer Research Center of the University of Washington in Seattle and the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Needle has held faculty positions at the University of Pennsylvania and Columbia University. Dr. Needle graduated from Binghamton University with a Bachelor of Arts in Physics and received his medical degree from SUNY Downstate Medical Center, in Brooklyn, New York.
Joseph Vittiglio, Esq.
SENIOR VICE PRESIDENT, GENERAL COUNSEL
Joseph Vittiglio joined AVEO in 2007 and has more than 15 years of experience in corporate and securities law, with a particular focus in the biotech and pharmaceutical industries. Prior to joining AVEO, Mr. Vittiglio was the director of corporate legal affairs of Oscient Pharmaceuticals from 2005 through 2007. From 1998 through 2005, Mr. Vittiglio was a senior attorney at the Boston law firm of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., where his practice focused principally in the life science and technology industries, working on collaborative arrangements, corporate partnering, registered public offerings, mergers and acquisitions and venture financings. Mr. Vittiglio sits on the Board of Directors of the Casa Monte Cassino in Boston and on the Board of Directors Lynnfield Youth Soccer. Mr. Vittiglio holds a degree in International Relations from Tufts University and graduated from Northeastern University School of Law in 1996.
Michael Boretti, Ph.D.
VICE PRESIDENT, CORPORATE DEVELOPMENT AND ALLIANCE MANAGEMENT
Michael Boretti serves as the Company’s Vice President of Corporate Development and Alliance Management, having joined AVEO in 2008 and bringing 10 years of business and strategy experience in the biopharmaceutical industry. While at AVEO, Dr. Boretti has lead strategic planning and business development activities, successfully establishing and managing licensing and collaboration agreements across several R&D programs. More recently, he has also served as program and alliance manager for tivozanib program. Prior to joining AVEO, Michael worked for three years as a strategy consultant in the Biopharma and Life Sciences Practice at L.E.K. Consulting. During his time at L.E.K., Michael completed more than 15 projects for biotech and pharmaceutical industry clients, providing strategic advice in the areas of business development, M&A transactions, product strategy, market assessments, and corporate planning. Dr. Boretti received a B.S. in Engineering Science with a minor in Biomedical Engineering from the University of Virginia, and a Ph.D. in Bioengineering from the University of Pennsylvania.
VICE PRESIDENT, CLINICAL OPERATOINS
Tiffany J. Crowell joined AVEO in 2011 and currently services as AVEO’s Vice President of Clinical Operations. Ms. Crowell has more than 20 years of experience in the biotech and pharmaceutical industries. Prior to joining AVEO, Ms. Crowell held positions of increasing responsibilities within clinical operations at Inotek Pharmaceuticals, Vertex Pharmaceuticals, Therion Biologics, VI Technologies, and Biopure Corporation. Prior to 1999, Ms. Crowell gained experience in the areas of process development, manufacturing, and research and development with Oravax, Repligen, Idexx, and Wyeth Ayerst Laboratories. Ms. Crowell received a B.S. in Chemistry from Randolph-Macon Woman’s College in 1986.
VICE PRESIDENT, FINANCE
Matt joined AVEO in 2011 and currently serves as AVEO’s Vice President of Finance. In this role Matt has responsibility for the Company’s Finance, IT, and Facilities functions. Prior to joining AVEO, Matt worked at Genzyme Corporation, NEN Life Sciences, and Kimberly-Clark Corporation where he held various positions in finance and accounting. Mr. Dallas has 17 years of finance experience including 15 in the Biotech/Life Science industry and holds a B.S. in Finance from the University of Tennessee in Knoxville.
Emile Farhan, Ph.D.
VICE PRESIDENT, TECHNICAL OPERATIONS
Emile Farhan has more than 20 years of experience in the pharmaceutical industry. As the Vice President of Technical Operations, he leads all aspects of chemistry, manufacturing and control of AVEO programs. He joined AVEO in April 2012 after his tenure at Eisai, where he served as the Head of CMC Global Operations Coordination for the US and Europe and as the Director of Pharmaceutical Development at MGI prior to its acquisition by Eisai. Prior to MGI, he served as the Senior Director of Product Development and Manufacturing at Mersana Therapeutics. Dr. Farhan also held several leadership roles at Pharm-Eco from 1992 until its acquisition by Johnson Matthey in 2000 and at Johnson Matthey Pharma from 2000 to 2006, where he was the Senior Director of Technical Operations and Scientific Affairs. Dr. Farhan holds a Ph.D. from Brandeis University and an MS from the University of Massachusetts.